SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announced positive Phase III SAFFRON trial results showing…

HUTCHMED (China) Ltd · 6-K filed Aug 17, 2026 at 06:19 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 17, 2026 at 06:19 ET

HUTCHMED announced positive Phase III SAFFRON trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) versus chemotherapy in MET-driven EGFR-mutated NSCLC patients who progressed on TAGRISSO. This is the first global Phase III trial to demonstrate both PFS and OS benefits in this setting, providing pivotal data to support global regulatory filings for the combination. The results de-risk the global registration pathway for ORPATHYS, a key pipeline asset co-developed with AstraZeneca, and address a significant unmet need in a large patient population.

  • SAFFRON Phase III trial met primary endpoint of PFS and key secondary endpoint of OS with statistical significance vs platinum-based chemotherapy.
  • Trial enrolled 338 patients across 230 centers in 29 countries.
  • ORPATHYS + TAGRISSO is already approved in China based on the SACHI Phase III trial; SAFFRON data supports global registrations.
  • Safety profile was consistent with known profiles of each medicine; no new safety findings.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access